Savara (SVRA) Stock Overview

A clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. More details

SVRA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 68.56% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

SVRA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW470,695 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

470,695 investors already sharing narratives

View all narratives

Savara Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Savara
Historical stock prices
Current Share Price	US$5.27
52 Week High	US$7.01
52 Week Low	US$2.68
Beta	0.26
1 Month Change	-7.38%
3 Month Change	4.77%
1 Year Change	75.08%
3 Year Change	53.20%
5 Year Change	331.97%
Change since IPO	-39.84%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SVRA	US Biotechs	US Market
7D	-9.0%	4.5%	1.0%
1Y	75.1%	38.3%	18.4%

Return vs Industry: SVRA exceeded the US Biotechs industry which returned 38.3% over the past year.

Return vs Market: SVRA exceeded the US Market which returned 18.4% over the past year.

Price Volatility

Is SVRA's price volatile compared to industry and market?
SVRA volatility
SVRA Average Weekly Movement	6.5%
Biotechs Industry Average Movement	10.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SVRA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SVRA's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2007	70	Matt Pauls	www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Savara Inc. Fundamentals Summary

How do Savara's earnings and revenue compare to its market cap?
SVRA fundamental statistics
Market cap	US$1.45b
Earnings (TTM)	-US$139.31m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-9.6x

P/E Ratio

Is SVRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SVRA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$86.84m
Gross Profit	-US$86.84m
Other Expenses	US$52.47m
Earnings	-US$139.31m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.55
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	20.4%

How did SVRA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/13 03:31
End of Day Share Price	2026/08/13 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Savara Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dewey Steadman	Canaccord Genuity
Liisa Bayko	Citizens JMP Securities, LLC
Jonathan Wolleben	Citizens JMP Securities, LLC